| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||
| Chlorophyllin is a semi-synthetic derivative of chlorophyll, the green pigment found in plants that is essential for photosynthesis. -Antioxidant Activity -Detoxification -Inhibition of Tumor Growth(unknown pathway?) -Modulation of Gene Expression -Anti-inflammatory Effects Dose: 100-300mg/d split 1-3x/d Chlorophyllin — Chlorophyllin is a semi-synthetic, water-soluble copper-containing derivative mixture of plant chlorophyll, most commonly used as sodium copper chlorophyllin. It is best classified as a semi-synthetic small-molecule phytochemical derivative that also functions as a food color additive, OTC deodorant drug ingredient, and chemopreventive “interceptor” candidate rather than a validated systemic anticancer drug. Standard abbreviations include CHL and, for the common oral form, SCC (sodium copper chlorophyllin). It originates from natural chlorophyll after saponification and copper substitution to improve water solubility and stability. The strongest translational evidence is for oral reduction of carcinogen bioavailability and DNA-adduct burden in exposure settings; direct tumoricidal signaling effects are mostly preclinical, and photodynamic use is a distinct external-trigger application. Chlorophyll (Chl), the parent compound of CHL, is readily available by consumption of green vegetables.Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral chlorophyllin is relatively digestive-stable and can interact with intestinal cells, but available PK data suggest limited systemic serum exposure, with significant luminal retention and efflux likely contributing to its dominant gastrointestinal interception profile. Some animal work suggests tissue distribution can occur, but standard oral use does not support assuming high free systemic tumor exposure. In-vitro vs systemic exposure relevance: Common direct anticancer in-vitro studies likely use concentrations above what is reliably achievable in systemic circulation with ordinary oral dosing. Its most credible non-PDT human effect is not high plasma tumor exposure but reduced carcinogen uptake and biomarker damage. In PDT contexts, efficacy is not ordinary concentration-driven alone and requires an external light trigger. Clinical evidence status: Human evidence is strongest for chemopreventive biomarker modulation, including a randomized placebo-controlled trial showing reduced aflatoxin biomarker burden in a high-risk population. Evidence for direct cancer treatment remains preclinical or adjunctive/emerging, while newer studies in radiation-related injury are not yet proof of anticancer efficacy. Mechanistic table
TSF legend: P: 0–30 min |
| Source: |
| Type: |
| Cytochrome c ** The term "release of cytochrome c" ** an increase in level for the cytosol. Small hemeprotein found loosely associated with the inner membrane of the mitochondrion where it plays a critical role in cellular respiration. Cytochrome c is highly water-soluble, unlike other cytochromes. It is capable of undergoing oxidation and reduction as its iron atom converts between the ferrous and ferric forms, but does not bind oxygen. It also plays a major role in cell apoptosis. The term "release of cytochrome c" refers to a critical step in the process of programmed cell death, also known as apoptosis. In its new location—the cytosol—cytochrome c participates in the apoptotic signaling pathway by helping to form the apoptosome, which activates caspases that execute cell death. Cytochrome c is a small protein normally located in the mitochondrial intermembrane space. Its primary role in healthy cells is to participate in the electron transport chain, a process that helps produce energy (ATP) through oxidative phosphorylation. Mitochondrial outer membrane permeability leads to the release of cytochrome c from the mitochondria into the cytosol. The release of cytochrome c is a pivotal event in apoptosis where cytochrome c moves from the mitochondria to the cytosol, initiating a chain reaction that leads to programmed cell death. On the one hand, cytochrome c can promote cancer cell survival and proliferation by regulating the activity of various signaling pathways, such as the PI3K/AKT pathway. This can lead to increased cell growth and resistance to apoptosis, which are hallmarks of cancer. On the other hand, cytochrome c can also induce apoptosis in cancer cells by interacting with other proteins, such as Apaf-1 and caspase-9. This can lead to the activation of the intrinsic apoptotic pathway, which can result in the death of cancer cells. Overexpressed in Breast, Lung, Colon, and Prostrate. Underexpressed in Ovarian, and Pancreatic. |
| 6069- | CHL, | PDT, | Anti-Cancer Effect of Chlorophyllin-Assisted Photodynamic Therapy to Induce Apoptosis through Oxidative Stress on Human Cervical Cancer |
| - | in-vitro, | Cerv, | HeLa |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:218 Target#:77 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid